Search

Your search keyword '"Michiels, Erna M. C."' showing total 16 results
Start Over "Michiels, Erna M. C."
16 results on '"Michiels, Erna M. C."'

2. A Dutch paediatric palliative care guideline: a systematic review and evidence-based recommendations for symptom treatment

Author

van Teunenbroek, Kim C., Mulder, Renée L., Ahout, Inge M. L., Bindels-de Heus, Karen G. C. B., Delsman-van Gelder, Catharina M., Galimont-Collen, Annemie F. S., de Groot, Marinka A. R., Heitink-Polle, Katja M. J., Looijestijn, Jeffry, Mensink, Maarten O., Mulder, Selma, Schieving, Jolanda H., Schouten-van Meeteren, Antoinette Y. N., Verheijden, Johannes M. A., Rippen, Hester, Borggreve, Brigitt C. M., Kremer, Leontien C. M., Verhagen, A. A. Eduard, and Michiels, Erna M. C.

Published
2024
Full Text
View/download PDF

5. Pain monitoring app leads to less pain in children with cancer at home: Results of a randomized controlled trial.

Author

Simon, Julia D. H. P., Schepers, Sasja A., van Gorp, Marloes, Michiels, Erna M. C., Fiocco, Marta, Grootenhuis, Martha A., and Tissing, Wim J. E.

Subjects
CANCER pain, RANDOMIZED controlled trials, CHILDHOOD cancer, DUTCH people, MOBILE apps
Abstract

Background: The authors developed a pain monitoring app offering educational information, and real‐time health care professional feedback on clinically significant pain (>4 numeric rating scale [NRS]‐11) for children with cancer to reduce pain at home. Methods: This monocenter, nonblinded randomized controlled trial enrolled Dutch children (0–18 years old) receiving cancer treatment (≥3 months after diagnosis, ≥2 months treatment remaining). Children were randomly assigned to use the app or receive usual care (two parallel groups). We assessed whether use of the app yielded less clinically significant pain (aim 1) and whether it affected pain severity, duration, interference, pain management strategies, and parental emotional well‐being (aim 2). The app was also evaluated by families (aim 3). Results: A total of 94 children were randomized to use the app (15 drop‐outs), and 90 were to receive care as usual (11 drop‐outs). The app group (n = 79, mean age: 7.5 [5.1] years, 48% girls, 63% hemato‐oncology diagnosis) reported significantly less clinically significant pain compared to usual care (n = 79, mean age: 7.5 [5.4] years, 52% girls, 65% hemato‐oncology diagnosis) (odds ratio [OR], 0.38; 95% confidence interval [CI], 0.198–0.734]) (aim 1), as well as significantly lower pain severity (β = –0.27; 95% CI, –0.407 to –0.142). No differences were found for duration, interference, or management strategies. Parents in the app group reported significantly less distress compared to usual care (β = –0.84; 95% CI, –1.61 to –0.03]) (aim 2). Families generally evaluated the app positively (aim 3). Conclusions: Use of the app resulted in less clinically significant pain at home. The exact working mechanisms of the app should be further elucidated. Use of a pain monitoring app with educational information on pain (management) and real‐time health care professional feedback reduced clinically significant pain in children with cancer at home. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Revisiting the Role of Immunotherapy for Colorectal Cancer Treatment in Patients with Constitutional Mismatch Repair Deficiency

Author

Eikenboom, Ellis L, Michiels, Erna M C, Grünhagen, Dirk J, de Vries, Marianne, Wagner, Anja, Spaander, Manon CW, Clinical Genetics, Gastroenterology & Hepatology, Surgery, and Radiology & Nuclear Medicine

Subjects
SDG 3 - Good Health and Well-being, General Earth and Planetary Sciences, General Environmental Science
Abstract

Patients with constitutional mismatch repair deficiency syndrome(CMMRD) usually develop multiple tumors at a young age. Chemotherapywas previously shown to be less effective in these tumors. Recent reportssuggest immunotherapeutic treatment in CMMRD-associated tumors. Here,we present a CMMRD patient, successfully treated with immunotherapyfor metastasized colorectal cancer (CRC). A young adolescent male wasdiagnosed with T2N2M1 cecum carcinoma with liver metastases. Hereceived four initial doses of nivolumab (3 mg/kg) with ipilimumab (1 ml/kg) every three weeks, followed by 41 doses of nivolumab alone every twoweeks. A complete response was achieved; also pathological assessmentof removed liver metastases was indicative of a complete response. Atthe time of writing, 14 months after end of treatment, the CRC had notrecurred. Immunotherapeutic treatment resulted in a complete response ofthe primary CRC and metastases. Immunotherapy as first line treatmentshould be strongly considered in treatment of CMMRD-associated CRCs

Published
2022
Full Text
View/download PDF

10. Subgroup-specific structural variation across 1,000 medulloblastoma genomes

Author

Northcott, Paul A., Shih, David J. H., Peacock, John, Garzia, Livia, Morrissy, Sorana A., Zichner, Thomas, Stütz, Adrian M., Korshunov, Andrey, Reimand, Jüri, Schumacher, Steven E., Beroukhim, Rameen, Ellison, David W., Marshall, Christian R., Lionel, Anath C., Mack, Stephen, Dubuc, Adrian, Yao, Yuan, Ramaswamy, Vijay, Luu, Betty, Rolider, Adi, Cavalli, Florence M. G., Wang, Xin, Remke, Marc, Wu, Xiaochong, Chiu, Readman Y. B., Chu, Andy, Chuah, Eric, Corbett, Richard D., Hoad, Gemma R., Jackman, Shaun D., Li, Yisu, Lo, Allan, Mungall, Karen L., Nip, Ka Ming, Qian, Jenny Q., Raymond, Anthony G. J., Thiessen, Nina, Varhol, Richard J., Birol, Inanc, Moore, Richard A., Mungall, Andrew J., Holt, Robert, Kawauchi, Daisuke, Roussel, Martine F., Kool, Marcel, Jones, David T. W., Witt, Hendrick, Fernandez-L, Africa, Kenney, Anna M., Wechsler-Reya, Robert J., Dirks, Peter, Aviv, Tzvi, Grajkowska, Wieslawa A., Perek-Polnik, Marta, Haberler, Christine C., Delattre, Olivier, Reynaud, Stéphanie S., Doz, François F., Pernet-Fattet, Sarah S., Cho, Byung-Kyu, Kim, Seung-Ki, Wang, Kyu-Chang, Scheurlen, Wolfram, Eberhart, Charles G., Fèvre-Montange, Michelle, Jouvet, Anne, Pollack, Ian F., Fan, Xing, Muraszko, Karin M., Gillespie, Yancey G., Di Rocco, Concezio, Massimi, Luca, Michiels, Erna M. C., Kloosterhof, Nanne K., French, Pim J., Kros, Johan M., Olson, James M., Ellenbogen, Richard G., Zitterbart, Karel, Kren, Leos, Thompson, Reid C., Cooper, Michael K., Lach, Boleslaw, McLendon, Roger E., Bigner, Darell D., Fontebasso, Adam, Albrecht, Steffen, Jabado, Nada, Lindsey, Janet C., Bailey, Simon, Gupta, Nalin, Weiss, William A., Bognár, László, Klekner, Almos, Van Meter, Timothy E., Kumabe, Toshihiro, Tominaga, Teiji, Elbabaa, Samer K., Leonard, Jeffrey R., Rubin, Joshua B., Liau, Linda M., Van Meir, Erwin G., Fouladi, Maryam, Nakamura, Hideo, Cinalli, Giuseppe, Garami, Miklós, Hauser, Peter, Saad, Ali G., Iolascon, Achille, Jung, Shin, Carlotti, Carlos G., Vibhakar, Rajeev, Ra, Young Shin, Robinson, Shenandoah, Zollo, Massimo, Faria, Claudia C., Chan, Jennifer A., Levy, Michael L., Sorensen, Poul H. B., Meyerson, Matthew, Pomeroy, Scott L., Cho, Yoon-Jae, Bader, Gary D., Tabori, Uri, Hawkins, Cynthia E., Bouffet, Eric, Scherer, Stephen W., Rutka, James T., Malkin, David, Clifford, Steven C., Jones, Steven J. M., Korbel, Jan O., Pfister, Stefan M., Marra, Marco A., and Taylor, Michael D.

Published
2012
Full Text
View/download PDF

11. Very long-term sequelae of craniopharyngioma

Author

Wijnen, Mark, primary, van den Heuvel-Eibrink, Marry M, additional, Janssen, Joseph A M J L, additional, Catsman-Berrevoets, Coriene E, additional, Michiels, Erna M C, additional, van Veelen-Vincent, Marie-Lise C, additional, Dallenga, Alof H G, additional, van den Berge, J Herbert, additional, van Rij, Carolien M, additional, van der Lely, Aart-Jan, additional, and Neggers, Sebastian J C M M, additional

Published
2017
Full Text
View/download PDF

12. Current variations in childhood cancer supportive care in the Netherlands

Author

Loeffen, Erik A. H., primary, Mulder, Renée L., additional, van de Wetering, Marianne D., additional, Font-Gonzalez, Anna, additional, Abbink, Floor C. H., additional, Ball, Lynne M., additional, Loeffen, Jan L. C. M., additional, Michiels, Erna M. C., additional, Segers, Heidi, additional, Kremer, Leontien C. M., additional, and Tissing, Wim J. E., additional

Published
2015
Full Text
View/download PDF

14. Cytogenetic prognostication within medulloblastoma subgroups

Author

Shih, David J. H., Northcott, Paul A., Remke, Marc, Korshunov, Andrey, Ramaswamy, Vijay, Kool, Marcel, Luu, Betty, Yao, Yuan, Wang, Xin, Dubuc, Adrian M., Garzia, Livia, Peacock, John, Mack, Stephen C., Wu, Xiaochong, Rolider, Adi, Morrissy, A. Sorana, Cavalli, Florence M. G., Jones, David T. W., Zitterbart, Karel, Faria, Claudia C., Schüller, Ulrich, Kren, Leo, Kumabe, Toshihiro, Tominaga, Teiji, Ra, Young Shin, Garami, Mikló, Hauser, Peter, Chan, Jennifer A., Robinson, Shenandoah, Bognár, László, Klekner, Almo, Saad, Ali G., Liau, Linda M., Albrecht, Steffen, Fontebasso, Adam, Cinalli, Giuseppe, De Antonellis, Pasqualino, Zollo, Massimo, Cooper, Michael K., Thompson, Reid C., Bailey, Simon, Lindsey, Janet C., Di Rocco, Concezio, Massimi, Luca, Michiels, Erna M. C., Scherer, Stephen W., Phillips, Joanna J., Gupta, Nalin, Fan, Xing, Muraszko, Karin M., Vibhakar, Rajeev, Eberhart, Charles G., Fouladi, Maryam, Lach, Boleslaw, Jung, Shin, Wechsler-Reya, Robert J., Fèvre-Montange, Michelle, Jouvet, Anne, Jabado, Nada, Pollack, Ian F., Weiss, William A., Lee, Ji-Yeoun, Cho, Byung-Kyu, Kim, Seung-Ki, Wang, Kyu-Chang, Leonard, Jeffrey R., Rubin, Joshua B., De Torres, Carmen, Lavarino, Cinzia, Mora, Jaume, Cho, Yoon-Jae, Tabori, Uri, Olson, James M., Gajjar, Amar, Packer, Roger J., Rutkowski, Stefan, Pomeroy, Scott L., French, Pim J., Kloosterhof, Nanne K., Kros, Johan M., Van Meir, Erwin G., Clifford, Steven C., Bourdeaut, Franck, Delattre, Olivier, Doz, François F., Hawkins, Cynthia E., Malkin, David, Grajkowska, Wieslawa A., Perek-Polnik, Marta, Bouffet, Eric, Rutka, James T., Pfister, Stefan M., Taylor, Michael D., Shih, David J. H., Northcott, Paul A., Remke, Marc, Korshunov, Andrey, Ramaswamy, Vijay, Kool, Marcel, Luu, Betty, Yao, Yuan, Wang, Xin, Dubuc, Adrian M., Garzia, Livia, Peacock, John, Mack, Stephen C., Wu, Xiaochong, Rolider, Adi, Morrissy, A. Sorana, Cavalli, Florence M. G., Jones, David T. W., Zitterbart, Karel, Faria, Claudia C., Schüller, Ulrich, Kren, Leo, Kumabe, Toshihiro, Tominaga, Teiji, Ra, Young Shin, Garami, Mikló, Hauser, Peter, Chan, Jennifer A., Robinson, Shenandoah, Bognár, László, Klekner, Almo, Saad, Ali G., Liau, Linda M., Albrecht, Steffen, Fontebasso, Adam, Cinalli, Giuseppe, De Antonellis, Pasqualino, Zollo, Massimo, Cooper, Michael K., Thompson, Reid C., Bailey, Simon, Lindsey, Janet C., Di Rocco, Concezio, Massimi, Luca, Michiels, Erna M. C., Scherer, Stephen W., Phillips, Joanna J., Gupta, Nalin, Fan, Xing, Muraszko, Karin M., Vibhakar, Rajeev, Eberhart, Charles G., Fouladi, Maryam, Lach, Boleslaw, Jung, Shin, Wechsler-Reya, Robert J., Fèvre-Montange, Michelle, Jouvet, Anne, Jabado, Nada, Pollack, Ian F., Weiss, William A., Lee, Ji-Yeoun, Cho, Byung-Kyu, Kim, Seung-Ki, Wang, Kyu-Chang, Leonard, Jeffrey R., Rubin, Joshua B., De Torres, Carmen, Lavarino, Cinzia, Mora, Jaume, Cho, Yoon-Jae, Tabori, Uri, Olson, James M., Gajjar, Amar, Packer, Roger J., Rutkowski, Stefan, Pomeroy, Scott L., French, Pim J., Kloosterhof, Nanne K., Kros, Johan M., Van Meir, Erwin G., Clifford, Steven C., Bourdeaut, Franck, Delattre, Olivier, Doz, François F., Hawkins, Cynthia E., Malkin, David, Grajkowska, Wieslawa A., Perek-Polnik, Marta, Bouffet, Eric, Rutka, James T., Pfister, Stefan M., and Taylor, Michael D.

Abstract

Purpose: Medulloblastoma comprises four distinct molecular subgroups: WNT, SHH, Group 3, and Group 4. Current medulloblastoma protocols stratify patients based on clinical features: patient age, metastatic stage, extent of resection, and histologic variant. Stark prognostic and genetic differences among the four subgroups suggest that subgroup-specific molecular biomarkers could improve patient prognostication. Patients and Methods: Molecular biomarkers were identified from a discovery set of 673 medulloblastomas from 43 cities around the world. Combined risk stratification models were designed based on clinical and cytogenetic biomarkers identified by multivariable Cox proportional hazards analyses. Identified biomarkers were tested using fluorescent in situ hybridization (FISH) on a nonoverlapping medulloblastoma tissue microarray (n = 453), with subsequent validation of the risk stratification models. Results: Subgroup information improves the predictive accuracy of a multivariable survival model compared with clinical biomarkers alone. Most previously published cytogenetic biomarkers are only prognostic within a single medulloblastoma subgroup. Profiling six FISH biomarkers (GLI2, MYC, chromosome 11 [chr11], chr14, 17p, and 17q) on formalin-fixed paraffin-embedded tissues, we can reliably and reproducibly identify very low-risk and very high-risk patients within SHH, Group 3, and Group 4 medulloblastomas. Conclusion: Combining subgroup and cytogenetic biomarkers with established clinical biomarkers substantially improves patient prognostication, even in the context of heterogeneous clinical therapies. The prognostic significance of most molecular biomarkers is restricted to a specific subgroup. We have identified a small panel of cytogenetic biomarkers that reliably identifies very high-risk and very low-risk groups of patients, making it an excellent tool for selecting patients for therapy intensification and therapy de-escalation in future clinical trials. © 2

Published
2014

16. Palliative care in children with cancer: implications for general practice.

Author

van der Geest, Ivana M. M., Bindels, Patrick J. E., Pluijm, Saskia M. F., Michiels, Erna M. C., van der Geest, Ivana Mm, Bindels, Patrick Je, Pluijm, Saskia Mf, Michiels, Erna Mc, van der Heide, Agnes, Pieters, Rob, Darlington, Anne-Sophie E, and van den Heuvel-Eibrink, Marry M

Subjects
PALLIATIVE treatment, CHILDHOOD cancer, CHILDREN'S health, GENERAL practitioners, FATIGUE (Physiology), PATIENTS
Abstract

The authors discuss the importance of palliative care, treatment that afford relief from disease but not cure, in children with cancer. Topics mentioned include the contribution of general practitioner (GP) in palliative care, the children health management, and the symptoms suffered by children with cancer at the end of life including fatigue, poor appetite, and pain.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results